Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.
Researchers of a new paper have targeted the basis for why a commonly used macrolide antibiotic for Clostridioides difficile infections (CDI) is able to target infection with minimal effect on the gut.
Fidaxomicin, now commonly used to treat CDI, selectively targets the bacterium while sparing crucial gut commensals that protect against C difficile infections. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.
In their paper, the researchers created a cryo-electron microscopy structure of C difficile RNA polymerase in complex with fidaxomicin, finding a single amino-acid residue in the zinc-binding-domain of the RNAP β′ subunit that serves as a sensitizing determinant for fidaxomicin.
C difficile is a Gram-positive, spore-forming, and toxin-producing intestinal bacterium that causes severe diarrhea. With a rise in infections caused by highly pathogenic variants, the CDC has designated C difficile an “urgent threat,” highlighting the need for effective treatment. While broad-spectrum antibiotics, such as vancomycin, have historically been used to treat CDI, they have been found to also negatively impact the gut microbiome and in turn allow for recurrent CDI.
“Although wide-spectrum antibiotics are broadly effective therapies, our results highlight the advantages of narrow-spectrum antibiotics to treat intestinal infections and probably other bacterial infections,” commented the researchers. “Treatment by narrow-spectrum antibiotics would reduce widespread antibiotic resistance and reduce the side effects caused by the collateral eradication of the beneficial bacteria in the gut microbiome. Using a similar approach to the one applied here, further elucidation of diverse bacterial RNAP structures and mechanisms can provide a blueprint for designer antibiotics that leverage natural microbial competition to combat pathogens more effectively.”
Using the outer-membrane weakener SPR741—a well-characterized outer-membrane weakener related to natural antibiotic colistin produced by a Firmicute—the researchers explored whether fidaxomicin resistance is dependent on the outer-membrane alone, the lack of positive charge residue on RNAP alone, or a combination of the 2. They found that both factors contributed to fidaxomicin resistance in E.coli in vivo, which the researchers said is relevant to the gut microbiome.
The group noted that while the exact presence of outer-membrane weakeners in the gut microbiome are unknown, there are other natural antibiotics generated by competing microbes in addition to colistin and medicinal antibiotics are often leveraged in combination.
“Conversely, a positively charged sensitizer (as found in CDI and Mtb) is crucial for conferring Fdx [fidaxomicin] sensitivity. Thus our studies enable the rational optimization of Fdx, depending on the target pathogen. For example, one might be able to substitute the phenolic oxygen with a stronger acid to treat Gram-positive pathogens or with a basic group to treat Gram-negative pathogens.”
Reference
Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell E. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. Published online April 6, 2022. doi: 10.1038/s41586-022-04545-z
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
A Conversation on the Past, Present, and Future of Public Health: NPHW 2023
April 3rd 2023For National Public Health Week this year, we sat down with Kristen Krause, PhD, MPH, instructor in the Department of Urban-Global Public Health and deputy director, Center for Health, Identity, Behavior and Prevention Studies, Rutgers School of Public Health.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More